Outcomes after transaortic transcatheter aortic valve implantation: long-term findings from the European ROUTE

Abstract OBJECTIVES There is lack of data regarding the longer-term outcomes of patients undergoing transaortic (TAo) transcatheter aortic valve implantation (TAVI). We aimed to provide a contemporary snapshot of the types and frequencies of events in the year following TAo-TAVI. METHODS The Registr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of cardio-thoracic surgery 2019-04, Vol.55 (4), p.737-743
Hauptverfasser: Cocchieri, Riccardo, Petzina, Rainer, Romano, Mauro, Jagielak, Dariusz, Bonaros, Nikolaos, Aiello, Marco, Lapeze, Joel, Laine, Mika, Chocron, Sidney, Muir, Douglas, Eichinger, Walter, Thielmann, Matthias, Labrousse, Louis, Rein, Kjell Arne, Verhoye, Jean-Philippe, Gerosa, Gino, Bapat, Vinayak, Baumbach, Hardy, Sims, Helen, Deutsch, Cornelia, Bramlage, Peter, Kurucova, Jana, Thoenes, Martin, Frank, Derk
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract OBJECTIVES There is lack of data regarding the longer-term outcomes of patients undergoing transaortic (TAo) transcatheter aortic valve implantation (TAVI). We aimed to provide a contemporary snapshot of the types and frequencies of events in the year following TAo-TAVI. METHODS The Registry of the Utilization of the TAo-TAVI approach using the Edwards SAPIEN Valve (ROUTE) is a multicentre, European, prospective, observational registry of aortic stenosis patients undergoing TAo-TAVI. Patients were grouped according to the composite end point death, myocardial infarction, stroke/transient ischaemic attack, major vascular complications, life-threatening bleeding, acute kidney injury (AKI) and/or cardiovascular rehospitalization. RESULTS Two hundred and fifty-three patients with a mean age of 81.5 ± 5.8 years were included, of whom 89 (35.2%) patients met the composite end point (the event group) and 164 (64.8%) patients did not (the event-free group). New York Heart Association (NYHA) class III/IV (85.2% vs 71.8%, P = 0.017), Canadian Cardiovascular Society angina class III/IV (22.6% vs 11.4%; P = 0.021), pulmonary disease (32.6% vs 18.9%; P = 0.015) and renal insufficiency (15.7% vs 3.0%; P 
ISSN:1010-7940
1873-734X
DOI:10.1093/ejcts/ezy333